Fairvalue-Calculator Fairvalue-Calculator
EN DE

Axogen, Inc (AXGN) Fair Value & Analysis

Healthcare · US · Market cap $2.3B

Price$44.69
Fair Value$10.90
Upside-75.6%
Quality95/100
Evidence: Low Range $8.18 – $13.63

Fair value as of: Jun 24, 2026

Analysis

Axogen, Inc (AXGN) currently trades at $44.69, while our model-based Fair Value estimate is $10.90 — implying the stock looks roughly 75.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisit…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -23% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Axogen, Inc (AXGN) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $10.90 versus a price of $44.69 — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of AXGN?
Our 21-model fair value for Axogen, Inc is $10.90 (as of Jun 24, 2026), built from audited fundamentals. The current price is $44.69.
What is the quality score of AXGN?
Axogen, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.